Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 15/20 | 0.80 |
| ▸ | BCL2 | P10415 | 8/20 | 0.80 |
| ▸ | MDM4 | O15151 | 1/20 | 0.80 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | BID | P55957 | 1/20 | 0.80 |
| ▸ | BAX | Q07812 | 1/20 | 0.80 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.80 |
| ▸ | ASPH | Q12797 | 1/20 | 0.80 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.80 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.80 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.80 |
| ▸ | BAD | Q92934 | 1/20 | 0.80 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1540670 | 0.91 | BCL2L1 (0.93) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL2022327 | 0.91 | BCL2L1 (0.80) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540944 | 0.90 | BCL2L1 (0.78) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL1540214 | 0.90 | BCL2L1 (0.92) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL158942 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL1541072 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL170470 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| Abt 737 SCHEMBL29355185 | 0.89 | BCL2L1 (1.00) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL2022329 | 0.89 | BCL2L1 (0.90) | BCL2L1BCL2MDM4BCL2L11TP53 | |
| SCHEMBL28901618 | 0.88 | BCL2L1 (0.83) | BCL2L1BCL2MDM4BCL2L11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-12527838-B2 | Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel | ALX Oncology Inc. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12287338-B2 | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-04-29 | — | — | US | disclosed |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2025-04-15 | — | — | US | disclosed |
| US-12221481-B2 | CD19 binding molecules and uses thereof | NOVARTIS AG (CH) | 2025-02-11 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240075101-A1 | COMBINATION THERAPIES FOR TREATING CANCER | ALX Oncology Inc. | 2024-03-07 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| CN-112852959-A | Methods and compositions for predicting anti-cancer efficacy of compounds targeting apoptotic pathways | 苏州亚盛药业有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2021-05-13 | — | — | US | disclosed |
| EP-3802611-A2 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2021-04-14 | — | — | EP | disclosed |
| EP-3774910-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20200392239-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER | IGM BIOSCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020236795-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236792-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236797-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| US-20200237670-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2019195535-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12287338-B2 | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway | BCL2, BAX, BCL2L1 | BCL2L1 3/4885BCL2 1/4885MDM4 206/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | BCL2L1 3069/4885BCL2 2976/4885MDM4 3199/4885 |
| US-20200237670-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, SCNN1B, HCCS | BCL2L1 470/4885BCL2 549/4885MDM4 3872/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | BCL2L1 425/4885BCL2 924/4885MDM4 1393/4885 |
| US-12221481-B2 | CD19 binding molecules and uses thereof | CD22, BCL9, CD2 | BCL2L1 390/4885BCL2 634/4885MDM4 3940/4885 |
| US-20200392239-A1 | USE OF A MULTIMERIC ANTI-DR5 BINDING MOLECULE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR TREATING CANCER | BAD, TNFSF10, TOP2A | BCL2L1 13/4885BCL2 8/4885MDM4 597/4885 |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | BCL2L1 390/4885BCL2 634/4885MDM4 3940/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | BCL2L1 61/4885BCL2 277/4885MDM4 2532/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | BCL2L1 390/4885BCL2 634/4885MDM4 3940/4885 |
| US-12527838-B2 | Combination therapies comprising an agent that blocks the interaction between CD47 and SIRPα for treating gastric or gastroesphageal junction cancel | CD47, ERBB2, FGFR2 | BCL2L1 1662/4885BCL2 1099/4885MDM4 3313/4885 |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | BCL2L1 418/4885BCL2 666/4885MDM4 3844/4885 |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | EPCAM, CD40, BCR | BCL2L1 425/4885BCL2 924/4885MDM4 1393/4885 |
| US-20240075101-A1 | COMBINATION THERAPIES FOR TREATING CANCER | FCGR2A, FCGR1A, FCGR3B | BCL2L1 1274/4885BCL2 1487/4885MDM4 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.